Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026
M&A / Deals UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies pharminent May 7, 2026
Clinical Data Celcuity strengthens case for ASCO-spotlighted breast cancer drug pharminent May 4, 2026
Clinical Data Summit shares descend as PD-1/VEGF asset misses early survival mark pharminent May 4, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
M&A / Deals AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B pharminent April 28, 2026
Clinical Data AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer pharminent April 28, 2026
Regulatory Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA pharminent April 27, 2026
Pipeline Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer pharminent April 24, 2026
Commercial Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs pharminent April 23, 2026
Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer pharminent April 21, 2026
Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Other AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle pharminent April 20, 2026
Other S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer pharminent April 20, 2026
Other S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting pharminent April 17, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
